TWI846843B - 適用於治療高血糖症的雜環基(苯基)甲醇化合物 - Google Patents

適用於治療高血糖症的雜環基(苯基)甲醇化合物 Download PDF

Info

Publication number
TWI846843B
TWI846843B TW109109482A TW109109482A TWI846843B TW I846843 B TWI846843 B TW I846843B TW 109109482 A TW109109482 A TW 109109482A TW 109109482 A TW109109482 A TW 109109482A TW I846843 B TWI846843 B TW I846843B
Authority
TW
Taiwan
Prior art keywords
methanol
dimethylpyrrolidin
compound
group
chlorophenyl
Prior art date
Application number
TW109109482A
Other languages
English (en)
Chinese (zh)
Other versions
TW202102473A (zh
Inventor
班傑明 佩爾曼
托爾 本傑森
Original Assignee
瑞典商阿特羅吉有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞典商阿特羅吉有限公司 filed Critical 瑞典商阿特羅吉有限公司
Publication of TW202102473A publication Critical patent/TW202102473A/zh
Application granted granted Critical
Publication of TWI846843B publication Critical patent/TWI846843B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW109109482A 2019-03-20 2020-03-20 適用於治療高血糖症的雜環基(苯基)甲醇化合物 TWI846843B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1903827.2 2019-03-20
GBGB1903827.2A GB201903827D0 (en) 2019-03-20 2019-03-20 New compounds and methods

Publications (2)

Publication Number Publication Date
TW202102473A TW202102473A (zh) 2021-01-16
TWI846843B true TWI846843B (zh) 2024-07-01

Family

ID=66381053

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109109482A TWI846843B (zh) 2019-03-20 2020-03-20 適用於治療高血糖症的雜環基(苯基)甲醇化合物

Country Status (13)

Country Link
US (1) US20220152004A1 (enExample)
EP (1) EP3941468A1 (enExample)
JP (1) JP2022525795A (enExample)
KR (1) KR20210141622A (enExample)
CN (1) CN113784953A (enExample)
AU (1) AU2020243426A1 (enExample)
BR (1) BR112021018578A2 (enExample)
CA (1) CA3133768A1 (enExample)
GB (1) GB201903827D0 (enExample)
IL (1) IL286432A (enExample)
MX (1) MX2021011286A (enExample)
TW (1) TWI846843B (enExample)
WO (1) WO2020188301A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
GB202204085D0 (en) * 2022-03-23 2022-05-04 Atrogi Ab New compounds and methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985887A (en) * 1973-10-19 1976-10-12 Smithkline Corporation 3-Substituted-4-hydroxyphenyl-2-piperidylcarbinols as β-adrenergic stimulants
WO1999065308A1 (en) * 1998-06-18 1999-12-23 Novartis Ag Composition for keeping away vermin

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3910933A (en) * 1973-10-19 1975-10-07 Smithkline Corp 3-Substituted-4-hydroxyphenyl-2-piperidylcarbinols
NO753594L (enExample) * 1974-10-30 1976-05-03 Scherico Ltd
FR2436779A1 (fr) * 1978-09-22 1980-04-18 Pharmindustrie Derives de pyrrolidine-2 methanol utilisables comme medicaments
FR2460929A1 (fr) * 1979-07-06 1981-01-30 Roussel Uclaf Nouveaux derives de l'a-phenyl 2-pyrrolidinemethanol et leur sels, procede de preparation, application a titre de medicaments et compositions les renfermant
EP0128120A3 (de) * 1983-06-02 1985-11-13 Ciba-Geigy Ag Trisubstituierte Oxazolidinone
PT1087662E (pt) * 1998-06-18 2002-09-30 Novartis Ag Composicao para manter afastada a vermina
GB0419828D0 (en) * 2004-09-07 2004-10-13 Arakis Ltd The treatment of inflammatroy disorders and pain
WO2006027579A2 (en) * 2004-09-07 2006-03-16 Sosei R & D Ltd. The treatment of inflammatory disorders and pain
GB2435979A (en) * 2006-03-07 2007-09-12 Helen Theresa Haywood Door intercom telephone device
FR2917735B1 (fr) * 2007-06-21 2009-09-04 Sanofi Aventis Sa Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique
GB201714740D0 (en) * 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985887A (en) * 1973-10-19 1976-10-12 Smithkline Corporation 3-Substituted-4-hydroxyphenyl-2-piperidylcarbinols as β-adrenergic stimulants
WO1999065308A1 (en) * 1998-06-18 1999-12-23 Novartis Ag Composition for keeping away vermin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Ferre P, et al. "Hypoglycemic effects of a β-agonist, Ro 16-8714, in streptozotocin-diabetic rats: devreased hepatic glucose production and increased glucose utilization in oxidative muscles" Metabolism 41(2): 1992 180-183 *

Also Published As

Publication number Publication date
US20220152004A1 (en) 2022-05-19
KR20210141622A (ko) 2021-11-23
EP3941468A1 (en) 2022-01-26
CA3133768A1 (en) 2020-09-24
MX2021011286A (es) 2022-01-24
IL286432A (en) 2021-10-31
GB201903827D0 (en) 2019-05-01
TW202102473A (zh) 2021-01-16
JP2022525795A (ja) 2022-05-19
CN113784953A (zh) 2021-12-10
AU2020243426A1 (en) 2021-11-04
WO2020188301A1 (en) 2020-09-24
BR112021018578A2 (pt) 2021-11-23

Similar Documents

Publication Publication Date Title
TWI846843B (zh) 適用於治療高血糖症的雜環基(苯基)甲醇化合物
ES2902073T3 (es) Beta-hidroxietilaminas sustituidas con heteroarilo para uso en el tratamiento de hiperglucemia
JP7346388B2 (ja) ベータ－ヒドロキシ複素環アミンおよび高血糖症の治療におけるそれらの使用
KR102849497B1 (ko) 플루오로페닐 베타-히드록시에틸아민 및 과혈당증의 치료에서의 이의 용도
TWI851687B (zh) 適用於治療高血糖症的雜芳基（雜環基）甲醇化合物
US11793774B2 (en) Chiral beta-hydroxyethylamines and their use in the treatment of hyperglycemia
TW202220956A (zh) 新穎芳基氮雜雙環［２．１．１］己基甲醇及其醫藥用途
TW202328071A (zh) 環己基β－羥基烷基胺類及其醫藥用途
TW202438055A (zh) 用於處置高血糖及高血糖為特徵的疾患之取代羥甲基吡咯啶類
TW202346299A (zh) 羥甲基氮雜雙環［２．２．１］庚烷及其醫藥用途
HK40033371B (en) Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia
HK40033371A (en) Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia